EUVIMEDEUVIMED entdecken
Crossref

Metformin is Protective Against the Development of Mood Disorders

Jacqueline Lake, Chiara C Bortolasci, Amanda L Stuart, Julie A Pasco, Srisaiyini Kidnapillai, Briana Spolding, Trang T T Truong, Bruna Panizzutti, Zoe S J Liu, Olivia M Dean, Tamsyn Crowley, Mark Richardson und 4 weitere

Pharmacopsychiatry · 01.01.2023 · 56 (01) · 25-31

DOI: 10.1055/a-1936-3580 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmacopsychiatry, erschienen am 01.01.2023. Verfasst von Jacqueline Lake und 15 weiteren Autor:innen. Beteiligte Einrichtung: Deakin University, IMPACT, The Institute for Mental and Physical Health and Clinical Translation, School of Medicine, Geelong, VIC, Australia. Hauptthemen laut MEDLINE: Metformin, Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 46 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Mood disorders are a major cause of disability, and current treatment options are inadequate for reducing the burden on a global scale. The aim of this project was to identify drugs suitable for repurposing to treat mood disorders.

Methods

This mixed-method study utilized gene expression signature technology and pharmacoepidemiology to investigate drugs that may be suitable for repurposing to treat mood disorders.

Results

The transcriptional effects of a combination of drugs commonly used to treat mood disorders included regulation of the steroid and terpenoid backbone biosynthesis pathways, suggesting a mechanism involving cholesterol biosynthesis, and effects on the thyroid hormone signaling pathway. Connectivity Map analysis highlighted metformin, an FDA-approved treatment for type 2 diabetes, as a drug having global transcriptional effects similar to the mood disorder drug combination investigated. In a retrospective cohort study, we found evidence that metformin is protective against the onset of mood disorders.

Discussion

These results provide proof-of-principle of combining gene expression signature technology with pharmacoepidemiology to identify potential novel drugs for treating mood disorders. Importantly, metformin may have utility in the treatment of mood disorders, warranting future randomized controlled trials to test its efficacy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MetforminDiabetes Mellitus, Type 2HumansMood DisordersRetrospective Studies

Substanzen

Metformin

Autor:innen und Institutionen

  • Deakin University, IMPACT, The Institute for Mental and Physical Health and Clinical Translation, School of Medicine, Geelong, VIC, Australia.
  • Department of Medicine-Western Health, University of Melbourne, St Albans, Australia.
  • Department of Epidemiology and Preventive Medicine, Monash University, Prahran, Australia.
  • Barwon Health, Geelong, Australia.
  • The Florey Institute of Neuroscience and Mental Health, Parkville, Australia.
  • Bioinformatics Core Research Facility (BCRF), Deakin University, Geelong, Australia.

Zitieren

APA

Lake, J., Bortolasci, C. C., Stuart, A. L., Pasco, J. A., Kidnapillai, S., Spolding, B., Truong, T. T. T., Panizzutti, B., Liu, Z. S. J., Dean, O. M., Crowley, T., Richardson, M., Kim, J. H., Berk, M., Williams, L. J., & Walder, K. (2023). Metformin is Protective Against the Development of Mood Disorders. Pharmacopsychiatry, 56(01), 25-31. https://doi.org/10.1055/a-1936-3580

Vancouver

Lake J, Bortolasci CC, Stuart AL, Pasco JA, Kidnapillai S, Spolding B, et al. Metformin is Protective Against the Development of Mood Disorders. Pharmacopsychiatry. 2023;56(01):25-31. doi:10.1055/a-1936-3580

BibTeX
@article{Lake2023,
  author = {Lake, Jacqueline and Bortolasci, Chiara C and Stuart, Amanda L and Pasco, Julie A and Kidnapillai, Srisaiyini and Spolding, Briana and Truong, Trang T T and Panizzutti, Bruna and Liu, Zoe S J and Dean, Olivia M and Crowley, Tamsyn and Richardson, Mark and Kim, Jee Hyun and Berk, Michael and Williams, Lana J and Walder, Ken},
  title = {Metformin is Protective Against the Development of Mood Disorders},
  journal = {Pharmacopsychiatry},
  year = {2023},
  volume = {56},
  number = {01},
  pages = {25--31},
  doi = {10.1055/a-1936-3580}
}
Kostenlos starten →